Last reviewed · How we verify
Breast cancer cohort
Breast cancer cohort is a HER2 inhibitor Biologic drug developed by Centre Leon Berard. It is currently in Phase 2 development for Adjuvant treatment of HER2-positive breast cancer.
This drug targets the HER2 protein to inhibit cancer cell growth.
This drug targets the HER2 protein to inhibit cancer cell growth. Used for Adjuvant treatment of HER2-positive breast cancer.
At a glance
| Generic name | Breast cancer cohort |
|---|---|
| Sponsor | Centre Leon Berard |
| Drug class | HER2 inhibitor |
| Target | HER2 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
The drug works by binding to the HER2 protein on the surface of cancer cells, which can lead to the inhibition of cancer cell growth and proliferation. This can help to slow or stop the growth of breast cancer tumors.
Approved indications
- Adjuvant treatment of HER2-positive breast cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Headache
- Muscle pain
Key clinical trials
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (PHASE1, PHASE2)
- Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (PHASE3)
- Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors (PHASE1)
- Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
- Epidemiology and Treatment of HR+/HER2- Breast Cancer in England
- Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer (PHASE1, PHASE2)
- A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors (PHASE2)
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Breast cancer cohort CI brief — competitive landscape report
- Breast cancer cohort updates RSS · CI watch RSS
- Centre Leon Berard portfolio CI
Frequently asked questions about Breast cancer cohort
What is Breast cancer cohort?
How does Breast cancer cohort work?
What is Breast cancer cohort used for?
Who makes Breast cancer cohort?
What drug class is Breast cancer cohort in?
What development phase is Breast cancer cohort in?
What are the side effects of Breast cancer cohort?
What does Breast cancer cohort target?
Related
- Drug class: All HER2 inhibitor drugs
- Target: All drugs targeting HER2
- Manufacturer: Centre Leon Berard — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Adjuvant treatment of HER2-positive breast cancer
- Compare: Breast cancer cohort vs similar drugs
- Pricing: Breast cancer cohort cost, discount & access